Abstract |
A prospective randomized, double-blind, placebo-controlled study was conducted to assess the efficacy and safety of nitazoxanide in the treatment of diarrhea caused by Giardia intestinalis or Entamoeba histolytica and/or E. dispar in 89 adults and adolescents, 22 of whom were diagnosed with G. intestinalis, 53 with E. histolytica and/or E. dispar, and 14 with both G. intestinalis and E. histolytica and/or E. dispar. The study medication was administered as 1 nitazoxanide 500-mg tablet or a matching placebo twice daily for 3 days. Thirty-eight (81%) of 47 patients in the nitazoxanide treatment group resolved diarrhea within 7 days (median, 3 days) after initiation of treatment, versus 17 (40%) of 42 in the placebo group (P=.0002). With its efficacy in treating a broad spectrum of enteric protozoan pathogens, nitazoxanide could play an important role in the management of diarrhea caused by enteric protozoa, reducing morbidity and costs associated with these diarrheal illnesses.
|
Authors | J F Rossignol, A Ayoub, M S Ayers |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 184
Issue 3
Pg. 381-4
(Aug 01 2001)
ISSN: 0022-1899 [Print] United States |
PMID | 11443569
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiprotozoal Agents
- Nitro Compounds
- Placebos
- Thiazoles
- nitazoxanide
|
Topics |
- Adolescent
- Adult
- Aged
- Animals
- Antiprotozoal Agents
(therapeutic use)
- Child
- Diarrhea
(drug therapy, parasitology)
- Double-Blind Method
- Dysentery, Amebic
(complications, drug therapy)
- Entamoeba
(isolation & purification)
- Entamoeba histolytica
(isolation & purification)
- Entamoebiasis
(complications, drug therapy)
- Feces
(parasitology)
- Female
- Giardia lamblia
(isolation & purification)
- Giardiasis
(complications, drug therapy)
- Humans
- Male
- Middle Aged
- Nitro Compounds
- Placebos
- Thiazoles
(therapeutic use)
|